Drink fluids on a schedule (4-6 ounces per hour while awake) rather than waiting for thirst, and choose electrolyte-containing fluids when sick
Common Adverse Reactions ( 2%): vaginitis (13.8%), headache (including migraine) (11.2%), mood changes (e.g., depression, mood swings, mood altered, depressed mood, affect lability) (6.4%), device-related events (e.g., expulsion/discomfort/foreign body sensation) (6.3%), nausea/vomiting (5.9%), vaginal discharge (5.7%), increased weight (4.9%), vaginal discomfort (4.0%), breast pain/discomfort/tenderness (3.8%), dysmenorrhea (3.5%), abdominal pain (3.2%), acne (2.4%), and decreased libido (2.0%)
These immunotherapeutic strategies demonstrate significant efficacy in the Panc02 pancreatic cancer model (208, 209)
Clinical studies on the dual GIP/GLP-1 receptor agonist, tirzepatide Tirzepatide has demonstrated significant weight loss effects in phase III clinical trials
Its mitochondria-targeted analog, MitoQ, provides stronger protection by reducing ROS, increasing GSH, and limiting apoptosis, thereby preserving mitochondrial integrity [111,112,113]
